We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





New Sensor Uses `Glow-in-the-Dark` Signal to Indicate Presence of Molecules Associated with COVID-19 in Blood

By LabMedica International staff writers
Posted on 29 Jul 2021
A new sensor with bioluminescent proteins indicates the presence of anti-drug antibodies and molecules associated with COVID-19 in the blood.

A research team at Eindhoven University of Technology (Eindhoven, Netherlands) and Utrecht University (Utrecht, the Netherlands) has developed a new type of sensor that combines the sensitivity and accuracy of current laboratory-based measurements with the speed and low-cost of current home tests. More...
The new sensor uses a “glow-in-the-dark” signal to indicate the presence of tiny amounts proteins and anti-drug antibodies, as well as COVID-19 spike proteins and antibodies in blood.

Home test kits to check for COVID-19 spike proteins and anti-COVID-19 antibodies are fast and simple to use but lack the sensitivity and accuracy of laboratory tests. Another issue with these so-called point-of-use home tests is that they are not accurate enough. With all of this in mind, the research team developed a new test approach with the accuracy and sensitivity of current laboratory-based methods and the speed and low-cost of existing point-of-use tests. The key to detecting and indicating the presence of biomarkers or molecules of interest is bioluminescence, the process that organisms such as fireflies use to produce light. The researchers tested the new sensing approach on a variety of biomarkers, including one to detect bacterial and viral infections (C-reactive protein), using 40 patient samples.

The RAPPID testing platform is definitely rapid in nature, and with a suitable sample holder can be used in conjunction with a smartphone, meaning that it has the potential to be used by anyone, anywhere. However, some work still needs to be done before his new testing platform will become available to the wider public.

“Our new sensor is based on bioluminescence, which we have used extensively in our previous research. If a certain protein or antibody is present in the sample, special proteins called luciferase enzymes will emit light,” said Maarten Merkx from the institute for Complex Molecular Systems (ICMS) at TU/e and research lead for the new study. “In other words, we look for a ‘glow-in-the-dark’ response.”

“We envisage that this testing platform could be used for a broad range of applications such as in rapid screening and testing, for therapeutic antibody-drug monitoring associated with conditions like rheumatoid arthritis and inflammatory bowel disease, and for the rapid detection of infectious diseases that could be associated with future epidemics or pandemics,” added Merkx.

Related Links:
Eindhoven University of Technology
Utrecht University



Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.